OTCPK:RNVA

Stock Analysis Report

Executive Summary

Rennova Health, Inc., together with its subsidiaries, provides a suite of healthcare related products and services to healthcare providers in the United States.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • Rennova Health has significant price volatility in the past 3 months.
  • Rennova Health's last earnings update was 313 days ago.
  • Rennova Health is not covered by any analysts.

Share Price & News

How has Rennova Health's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

100.0%

RNVA

-0.3%

US Healthcare

-0.6%

US Market


1 Year Return

-99.9%

RNVA

-9.2%

US Healthcare

0.7%

US Market

RNVA underperformed the Healthcare industry which returned -9.1% over the past year.

RNVA underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

RNVAIndustryMarket
7 Day100.0%-0.3%-0.6%
30 Day100.0%2.1%4.9%
90 Day100.0%-0.8%1.7%
1 Year-99.9%-99.9%-7.8%-9.2%3.0%0.7%
3 Year-100.0%-100.0%29.7%24.4%44.8%35.4%
5 Yearn/a66.1%56.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is Rennova Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Rennova Health undervalued based on future cash flows and its price relative to the stock market?


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Rennova Health to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Rennova Health to establish if it is available at substantial discount.


Price Based on Earnings

Rennova Health has no earnings, we can't compare its value to the US Healthcare industry average.

Rennova Health has no earnings, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Rennova Health, we can't assess if its growth is good value.


Price Based on Value of Assets

Rennova Health has negative assets, we can't compare the value of its assets to the US Healthcare industry average.


Next Steps

Future Growth

How is Rennova Health expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rennova Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of RNVA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Rennova Health's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Rennova Health performed over the past 5 years?

-63.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Rennova Health does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Rennova Health's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Rennova Health's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Rennova Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Rennova Health has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Rennova Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Rennova Health's financial position?


Financial Position Analysis

Rennova Health's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Rennova Health's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Rennova Health has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Rennova Health's debt level has increased considering it has negative shareholder equity.

Operating cash flow is negative therefore debt is not well covered.

Unable to confirm if the interest payments on Rennova Health's debt are well covered by earnings due to lack of past financial data.


Balance Sheet

High level of physical assets or inventory.

Rennova Health has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Next Steps

Dividend

What is Rennova Health's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Rennova Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Rennova Health's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Rennova Health has not reported any payouts.

Unable to verify if Rennova Health's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Rennova Health has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Rennova Health's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Seamus Lagan (50yo)

3.8yrs

Tenure

US$345,250

Compensation

Mr. Seamus Lagan has been the Chief Executive Officer and President at Rennova Health, Inc. since November 02, 2015 and its Interim Chief Financial Officer since May 10, 2019. Mr. Lagan served as Interim C ...


Management Age and Tenure

3.3yrs

Average Tenure

The tenure for the Rennova Health management team is about average.


Board Age and Tenure

3.6yrs

Average Tenure

60yo

Average Age

The tenure for the Rennova Health board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Sebastien Sainsbury

    Company Secretary & Public Relations

    • Tenure: 0yrs
    • Compensation: US$143.27k
  • Al Lechner

    Executive Vice President of Sales - Rennova Health Technology Solutions

    • Tenure: 3.8yrs
  • Seamus Lagan (50yo)

    President

    • Tenure: 3.8yrs
    • Compensation: US$345.25k
  • Karen Taylor

    Director of Human Resources

    • Tenure: 3.3yrs
  • Kristi Dymond

    Treasurer

    • Tenure: 1.4yrs
  • Michael Alexander

    CEO of Jamestown Medical Center

    • Tenure: 0.3yrs

Board Members

  • George Lundberg (86yo)

    Member of Scientific Advisory Committee

    • Tenure: 3.6yrs
    • Compensation: US$162.99k
  • Gary Blum (78yo)

    Independent Director

    • Tenure: 1.9yrs
    • Compensation: US$10.00k
  • Paul Billings (67yo)

    Member of Scientific Advisory Committee

    • Tenure: 3.6yrs
    • Compensation: US$38.34k
  • Chris Diamantis (50yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$66.00k
  • Asad Zaidi

    Member of Scientific Advisory Committee

    • Tenure: 3.6yrs
  • Seamus Lagan (50yo)

    President

    • Tenure: 3.8yrs
    • Compensation: US$345.25k
  • Kamran Ajami (60yo)

    Independent Director & Member of Scientific Advisory Committee

    • Tenure: 2.4yrs
    • Compensation: US$97.01k
  • Christopher Mason

    Member of Scientific Advisory Committee

    • Tenure: 3.6yrs
  • Trevor Langley (57yo)

    Independent Director

    • Tenure: 2.4yrs
    • Compensation: US$93.50k

Company Information

Rennova Health, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Rennova Health, Inc.
  • Ticker: RNVA
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.302m
  • Shares outstanding: 6.51b
  • Website: https://www.rennovahealth.com

Number of Employees


Location

  • Rennova Health, Inc.
  • 400 South Australian Avenue
  • 8th Floor
  • West Palm Beach
  • Florida
  • 33401
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RNVAOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 2015

Biography

Rennova Health, Inc., together with its subsidiaries, provides a suite of healthcare related products and services to healthcare providers in the United States. The company operates in three segments: Labo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/23 00:16
End of Day Share Price2019/09/20 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.